Comparative Pharmacology
Head-to-head clinical analysis: MINIPRESS versus TERAZOSIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINIPRESS versus TERAZOSIN HYDROCHLORIDE.
MINIPRESS vs TERAZOSIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors, inhibiting vasoconstriction and reducing peripheral vascular resistance.
Selective alpha-1 adrenergic receptor antagonist; inhibits vasoconstriction and relaxes smooth muscle in blood vessels and prostate.
Initial: 1 mg orally 2-3 times daily. Maintenance: 2-5 mg orally 2-3 times daily. Maximum: 20 mg/day.
Adults: Initial: 1 mg orally once daily at bedtime. May increase gradually to 2–5 mg once daily. Maximum: 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours; clinical effect persists longer (up to 24 hours) due to sustained receptor binding.
Terminal elimination half-life is 9–12 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily hepatic metabolism (90%) with <10% excreted unchanged in urine; 50-60% of metabolites eliminated in bile/feces, 40-50% in urine.
Approximately 40% of the dose is excreted in urine (20% as unchanged drug) and 60% in feces via biliary elimination.
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker